zilucoplan (CHEBI:229659)

Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search

CHEBI:229659 - zilucoplan

ChEBI ID	CHEBI:229659
ChEBI Name	zilucoplan
Stars
Definition	A 15 amino-acid, synthetic macrocyclic peptide with formula C₁₇₂H₂₇₈N₂₄O₅₅. Its sodium salt is used for the treatment of generalised myasthenia gravis (a disease that leads to muscle weakness and tiredness) in adults whose immune system produces antibodies against acetylcholine receptors.
Last Modified	16 April 2024
Submitter	Adnan
Downloads	Molfile

Formula	C172H278N24O55
Net Charge	0
Average Mass	3562.229
Monoisotopic Mass	3559.96944
SMILES	CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1cnc2ncccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)N(C)C(=O)[C@@H]1CC(=O)NCCCC[C@H](NC(C)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1)C(C)(C)C)C1CCCCC1)C(=O)O)C(=O)O
InChI	InChI=1S/C172H278N24O55/c1-9-10-11-12-13-14-15-16-17-18-19-20-27-44-146(202)182-136(170(226)227)53-56-144(200)177-64-67-229-69-71-231-73-75-233-77-79-235-81-83-237-85-87-239-89-91-241-93-95-243-97-99-245-101-103-247-105-107-249-109-111-251-113-112-250-110-108-248-106-104-246-102-100-244-98-96-242-94-92-240-90-88-238-86-84-236-82-80-234-78-76-232-74-72-230-70-68-228-66-59-145(201)175-60-31-29-41-135(169(224)225)186-165(220)152(126-37-25-22-26-38-126)193-162(217)142-43-34-65-196(142)168(223)140(116-125-47-51-129(199)52-48-125)190-157(212)133(54-57-148(204)205)184-161(216)139(117-127-120-180-154-130(127)39-32-62-178-154)188-159(214)138(115-124-45-49-128(198)50-46-124)189-166(221)153(172(5,6)7)194-163(218)143(119-150(208)209)195(8)167(222)141-118-147(203)176-61-30-28-40-131(181-122(4)197)158(213)192-151(121(2)3)164(219)185-134(55-58-149(206)207)156(211)183-132(42-33-63-179-171(173)174)155(210)187-137(160(215)191-141)114-123-35-23-21-24-36-123/h21,23-24,32,35-36,39,45-52,62,120-121,126,131-143,151-153,198-199H,9-20,22,25-31,33-34,37-38,40-44,53-61,63-119H2,1-8H3,(H,175,201)(H,176,203)(H,177,200)(H,178,180)(H,181,197)(H,182,202)(H,183,211)(H,184,216)(H,185,219)(H,186,220)(H,187,210)(H,188,214)(H,189,221)(H,190,212)(H,191,215)(H,192,213)(H,193,217)(H,194,218)(H,204,205)(H,206,207)(H,208,209)(H,224,225)(H,226,227)(H4,173,174,179)/t131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,151-,152-,153+/m0/s1
InChIKey	JDXCOXKBIGBZSK-PSNKNOTQSA-N

Wikipedia

Roles Classification

Chemical Role:	Bronsted base A molecular entity capable of accepting a hydron from a donor (Brønsted acid).
Biological Roles:	immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. complement component 5 inhibitor Any inhibitor of complement component 5.
Application:	immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response.

ChEBI Ontology

Outgoing Relation(s)
	zilucoplan (CHEBI:229659) has role complement component 5 inhibitor (CHEBI:229668)
	zilucoplan (CHEBI:229659) has role immunosuppressive agent (CHEBI:35705)
	zilucoplan (CHEBI:229659) is a homodetic cyclic peptide (CHEBI:24613)
	zilucoplan (CHEBI:229659) is a macrocycle (CHEBI:51026)
	zilucoplan (CHEBI:229659) is a polyether (CHEBI:46774)
	zilucoplan (CHEBI:229659) is conjugate acid of zilucoplan(4−) (CHEBI:229671)
Incoming Relation(s)
Incoming Relation(s)	zilucoplan(4−) (CHEBI:229671) is conjugate base of zilucoplan (CHEBI:229659)

IUPAC Name
N-{[(2S,5S,8S,11S,14S,22S)-22-acetamido-11-benzyl-8-(3-carbamimidamidopropyl)-5-(2-carboxyethyl)-3,6,9,12,16,23-hexaoxo-2-(propan-2-yl)-1,4,7,10,13,17-hexaazacyclotricosan-14-yl]carbonyl}-N-methyl-L-α-aspartyl-3-methyl-L-valyl-L-tyrosyl-3-(1H-pyrrolo[2,3-b]pyridin-3-yl)-L-alanyl-L-α-glutamyl-L-tyrosyl-N-{(1S,4S)-4-carboxy-1-cyclohexyl-84-[(N-hexadecanoyl-L-γ-glutamyl)amino]-2,10-dioxo-13,16,19,22,25,28,31,34,37,40,43,46,49,52,55,58,61,64,67,70,73,76,79,82-tetracosaoxa-3,9-diazatetraoctacont-1-yl}-L-prolinamide

IUPAC Name

N-{[(2S,5S,8S,11S,14S,22S)-22-acetamido-11-benzyl-8-(3-carbamimidamidopropyl)-5-(2-carboxyethyl)-3,6,9,12,16,23-hexaoxo-2-(propan-2-yl)-1,4,7,10,13,17-hexaazacyclotricosan-14-yl]carbonyl}-N-methyl-L-α-aspartyl-3-methyl-L-valyl-L-tyrosyl-3-(1H-pyrrolo[2,3-b]pyridin-3-yl)-L-alanyl-L-α-glutamyl-L-tyrosyl-N-{(1S,4S)-4-carboxy-1-cyclohexyl-84-[(N-hexadecanoyl-L-γ-glutamyl)amino]-2,10-dioxo-13,16,19,22,25,28,31,34,37,40,43,46,49,52,55,58,61,64,67,70,73,76,79,82-tetracosaoxa-3,9-diazatetraoctacont-1-yl}-L-prolinamide

INNs	Source
zilucoplan	WHO MedNet
zilucoplanum	WHO MedNet
zilucoplán	WHO MedNet
zilucoplan	WHO MedNet

Synonyms	Source
RA101495	DrugBank
RA3193	ChEBI
RA 101495	ChEBI
RA-101495	ChEBI

Manual Xrefs	Databases
DB15636	DrugBank
D12357	KEGG DRUG
Zilucoplan	Wikipedia

Registry Numbers	Sources
CAS:1841136-73-9	DrugBank

Citations